Biocon Finalizes Merger Between Covidshield And Biologics Business
Biocon Biologics Will Have Access To 100 Million Vaccine Doses Each Year
The merger between Serum Institute of India subsidiary Covidshield Technologies and Biocon Biologics has finally completed, subject to requisite approvals, after a Biocon board meeting.
